| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | IL2RB; IL15RB; P70-75 |
| Entrez GeneID | 3560 |
| clone | 1G11C6 |
| WB Predicted band size | 61kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD122 (AA: extra 27-240) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD122抗体的3篇示例文献(注：内容为模拟虚构，仅供参考)：
1. **文献名称**：*Targeting CD122 enhances NK cell activation and antitumor immunity*
**作者**：Zhang et al., 2021
**摘要**：研究开发了一种人源化抗CD122激动型抗体，通过增强IL-2信号通路，显著提升自然杀伤(NK)细胞活性，并在小鼠模型中抑制黑色素瘤生长，为癌症免疫治疗提供新策略。
2. **文献名称**：*CD122 blockade inhibits autoreactive T cells in experimental autoimmune encephalomyelitis*
**作者**：Kumar et al., 2019
**摘要**：通过抗CD122抗体阻断IL-2受体β亚基，抑制自身反应性T细胞的增殖和分化，有效缓解多发性硬化症模型小鼠的神经炎症，提示其在自身免疫疾病治疗中的潜力。
3. **文献名称**：*Engineered anti-CD122 antibody-drug conjugate for targeted T-cell lymphoma therapy*
**作者**：Chen et al., 2022
**摘要**：该研究构建了靶向CD122的抗体-药物偶联物(ADC)，在体外和体内实验中选择性杀伤T细胞淋巴瘤细胞，同时减少对正常免疫细胞的影响，为血液肿瘤治疗提供新方向。
4. **文献名称**：*CD122-directed bispecific antibody enhances viral-specific T cell responses in chronic infection*
**作者**：Wang et al., 2020
**摘要**：设计了一种靶向CD122和病毒抗原的双特异性抗体，通过增强IL-2信号与抗原呈递协同作用，恢复慢性病毒感染模型中的T细胞功能，为抗病毒免疫治疗提供新思路。
(注：上述文献为示例，非真实存在。实际研究中建议通过PubMed等数据库检索具体文献。)
CD122. also known as interleukin-2 receptor beta (IL-2Rβ), is a subunit of the IL-2 receptor complex expressed on immune cells, including T cells, B cells, and natural killer (NK) cells. It pairs with the common gamma chain (γc, CD132) to form a functional receptor for IL-2 and IL-15. cytokines critical for lymphocyte activation, proliferation, and homeostasis. CD122 is particularly important in regulating effector and memory T cell responses, as well as NK cell function.
CD122-targeting antibodies are designed to modulate immune activity by either blocking or activating this receptor pathway. In therapeutic contexts, antagonistic anti-CD122 antibodies have been explored to suppress excessive immune activation in autoimmune diseases or organ transplantation by interfering with IL-2/IL-15 signaling. Conversely, agonistic antibodies may enhance antitumor immunity by promoting T cell or NK cell activity, potentially synergizing with checkpoint inhibitors.
Research applications of CD122 antibodies include flow cytometry for immune cell profiling, functional studies of IL-2/IL-15 pathways, and preclinical models of cancer or autoimmunity. Challenges in targeting CD122 involve balancing its dual roles in pro-inflammatory and regulatory immune subsets (e.g., effector T cells vs. Tregs). Recent studies also investigate its combination with cytokine therapies to optimize specificity and reduce systemic toxicity.
×
